Optum notable drugs nearing FDA approval include Anaphylm, Sotyktu, and insulin icodec with decisions expected early 2026.

Senators are calling UnitedHealth Group’s response to an investigation "inadequate" and demanding more information following ...

ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” ...

UnitedHealth Group, Inc’s. UNH Optum Rx is expanding its offerings for patients with the introduction of two additional HUMIRA biosimilars. Effective Jul 1, Optum Rx will offer three biosimilar ...

UnitedHealth Group's 2024 revenues hit $400.3 billion in 2024 – a 6% year-over-year increase – and full-year earnings from operations were $32.3 billion. CEO Andrew Witty attributed much of this ...

After a multi-year battle, the $3.3 billion acquisition of home health provider Amedisys by UnitedHealth Group’s Optum may finally go through. The Department of Justice (DOJ) has reached a proposed ...

Optum on Tuesday launched the venture fund Optum Ventures, which has $250 million to invest in digital health startup companies. The venture fund will invest in companies that use data and insights to ...

The top brass at UnitedHealth Group offered investors a look at the company's efforts to right the ship after several rough financial quarters. CEO Stephen Hemsley said that 2026 is shaping up to be a ...

The U.S. Department of Justice’s criminal probe into UnitedHealth Group Incorporated UNH is broader than previously reported, per Bloomberg. While investigators had already been looking at its ...